A higher dose of an emergency-contraception drug may open a back door for Americans seeking abortions in restrictive states.

The new Trump administration could put a stop to pending litigation on the abortion pill mifepristone and other federal abortion policies through changes at the Department of Health and Human Services, according to a top anti-abortion lawyer involved in several pending cases.

Missouri, Kansas and Idaho can press forward with their lawsuit to restrict access to the abortion drug mifepristone, a federal judge ruled Thursday, months after the US Supreme Court had rejected an earlier version of the legal challenge.

Trump-appointed judge revives suit to restrict abortion pills access in latest salvo on reproductive rights - The federal judge’s order came less than a week before the 52nd anniversary of Roe

Three Republican-led states will be allowed to move forward with a lawsuit to restrict access to mifepristone, a Texas federal judge ruled Thursday, months after the Supreme Court rejected an

The website reproductiverights.gov is no longer online. Based on archived pages, the website was online just days before Trump's inauguration. However, we do not know why the site is down and have reached out to the Trump administration to learn more.

The three states argue that the FDA's approval of mifepristone for use up to 10 weeks of pregnancy, along with its availability via telemedicine and mail, has contributed to what they view as a public health risk.

Here are some of the actions Trump’s nominees could take on abortion, if confirmed, from HHS to the Justice Department.

Idaho, Kansas and Missouri want the federal Food and Drug Administration to prohibit telehealth prescriptions for mifepristone and require that it be used only in the first seven weeks of

With contraception rights under scrutiny nationwide, Virginia Democrats are doubling down on efforts to safeguard access, even as they brace for potential pushback from Gov. Glenn Youngkin.

The Biden administration had defended the FDA’s regulatory approach to mifepristone at the Supreme Court last year. The Trump transition team did not respond to a CNN inquiry about the case.

Previously, Kacsmaryk sided with a group of anti-abortion doctors and organizations that wanted the FDA to be forced to rescind entirely its approval of mifepristone in 2000. The Supreme Court ...